Payment overview · 2025
General Payments
$678.50
47 reported records · 16 companies
Healthcare provider profile · identity verified
Stephen L Harless, MD
Allopathic & Osteopathic Physicians|Family Medicine · PURVIS, MS · NPI 1336151976
Verified facts
What the public records show
CMS Open Payments records show Stephen L Harless, MD received $678.50 in general payments during 2025 across 47 reported records.
Novo Nordisk Inc accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 301 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.86 | 22.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.92 | 21.1% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.40 | 8.6% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $42.28 | 6.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.17 | 6.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.81 | 5.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.28 | 5.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $33.80 | 5.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.06 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.20 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.14 | 2.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.84 | 2.2% | 1 | 2025 |
| CapsoVision, Inc. | Unresolved — no canonical attribution shown | $14.67 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.94 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.63 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $678.50 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $124.92 | 16 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $86.68 | 12 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.83 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.28 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33.80 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.85 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| CapsoCam Plus Normalized: capsocam plus |
Device | CapsoVision, Inc. | $14.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 110 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 116 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
116 | 85 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
301 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1055 | 249 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1031 | 251 |
| Amlodipine Besylate | Amlodipine Besylate | 767 | 185 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 752 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 720 | 183 |
| Gabapentin | Gabapentin | 644 | 128 |
| Furosemide | Furosemide | 617 | 161 |
| Diclofenac Sodium | Diclofenac Sodium | 579 | 164 |
| Tizanidine Hcl | Tizanidine Hcl | 479 | 118 |
| Cefuroxime | Cefuroxime Axetil | 422 | 292 |
| Meloxicam | Meloxicam | 420 | 98 |
| Metformin Hcl | Metformin Hcl | 410 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 387 | 83 |
| Glimepiride | Glimepiride | 379 | 92 |
| Trazodone Hcl | Trazodone Hcl | 374 | 84 |
| Alprazolam | Alprazolam | 327 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 321 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 86 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 81 |
| Jardiance | Empagliflozin | 301 | 49 |
| Simvastatin | Simvastatin | 282 | 68 |
| Omeprazole | Omeprazole | 277 | 75 |
| Allopurinol | Allopurinol | 267 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 267 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 255 | 47 |
| Losartan Potassium | Losartan Potassium | 254 | 64 |
| Pioglitazone Hcl | Pioglitazone Hcl | 253 | 54 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 234 | 71 |
| Lisinopril | Lisinopril | 226 | 55 |
| Mupirocin | Mupirocin | 224 | 115 |
| Potassium Chloride | Potassium Chloride | 223 | 55 |
| Valsartan | Valsartan | 210 | 44 |
| Ramipril | Ramipril | 209 | 50 |
| Ondansetron Odt | Ondansetron | 185 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 176 | 40 |
| Ropinirole Hcl | Ropinirole Hcl | 176 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 152 | 42 |
| Pregabalin | Pregabalin | 152 | 30 |
| Tramadol Hcl | Tramadol Hcl | 151 | 30 |
| Azithromycin | Azithromycin | 149 | 124 |
| Metformin Hcl Er | Metformin Hcl | 143 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 28 |
| Montelukast Sodium | Montelukast Sodium | 117 | 25 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 116 | 85 |
| Warfarin Sodium | Warfarin Sodium | 115 | 18 |
| Ezetimibe | Ezetimibe | 114 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 114 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 113 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 111 | 29 |
| Levofloxacin | Levofloxacin | 111 | 97 |
| Buspirone Hcl | Buspirone Hcl | 110 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 110 | 65 |
| Eliquis | Apixaban | 110 | 23 |
| Sertraline Hcl | Sertraline Hcl | 110 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 108 | 28 |
| Meclizine Hcl | Meclizine Hcl | 106 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 76 |
| Carvedilol | Carvedilol | 100 | 26 |
| Methylprednisolone | Methylprednisolone | 99 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 26 |
| Alendronate Sodium | Alendronate Sodium | 96 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 23 |
| Fluconazole | Fluconazole | 86 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 22 |
| Celecoxib | Celecoxib | 83 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 75 | 21 |
| Sucralfate | Sucralfate | 75 | 22 |
| Synthroid | Levothyroxine Sodium | 75 | 20 |
| Bupropion Xl | Bupropion Hcl | 73 | 18 |
| Januvia | Sitagliptin Phosphate | 72 | suppressed |
| Spironolactone | Spironolactone | 72 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 68 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | 12 |
| Ozempic | Semaglutide | 65 | 12 |
| Famotidine | Famotidine | 63 | 16 |
| Baclofen | Baclofen | 61 | 16 |
| Mounjaro | Tirzepatide | 60 | 13 |
| Prednisone | Prednisone | 60 | 31 |
| Nystatin | Nystatin | 59 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 52 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Metolazone | Metolazone | 50 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 14 |
| Donepezil Hcl | Donepezil Hcl | 45 | suppressed |
| Finasteride | Finasteride | 44 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | 11 |
| Linzess | Linaclotide | 42 | 16 |
| Topiramate | Topiramate | 41 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 32 | 32 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 30 | 25 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Cefdinir | Cefdinir | 28 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 17 |
| Atenolol | Atenolol | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 27 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 27 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 24 | 16 |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 20 |
| Torsemide | Torsemide | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Cilostazol | Cilostazol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Sulindac | Sulindac | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Clarithromycin | Clarithromycin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $678.50 · 47 records | Novo Nordisk Inc | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, CapsoCam Plus, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Kerendia, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, Wegovy, ZAVZPRET, ZEPBOUND, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error